STOCKHOLM, SWEDEN / RankWire.AI / – Karl Deisseroth, Peter Hegemann and Georg Nagel have been awarded the 2026 Nobel Prize in Physiology or Medicine for their pioneering discoveries that laid the foundation for optogenetics. The Nobel Assembly at Karolinska Institutet announced the honor on October 5. Their groundbreaking work provided scientists with a precise method to control specific nerve cells using light. This technique now plays a key role in studying brain circuits, behavior, memory, and disease. It has become one of neuroscience’s most vital experimental tools.
Hegemann and Nagel revealed how channelrhodopsin functions in the green alga Chlamydomonas. This protein creates a light-sensitive channel within the cell membrane. When blue light hits it, the channel opens and allows charged ions to flow through. This movement can trigger electrical activity inside the cell. Their experiments demonstrated that scientists could insert channelrhodopsin into other cells and make them respond to light. This discovery laid the groundwork for controlling cell activity with light flashes.
Deisseroth adapted this finding for neuroscience. In 2005, he proved that channelrhodopsin could make rat nerve cells respond to blue light. His research showed that light could induce electrical signals in specific neurons. Later, the technique was successfully applied in living animals. These results helped establish optogenetics as a practical tool for exploring how brain circuits influence activity and behavior. It provided a much greater level of precision than earlier methods.
Light-based control revolutionizes brain research
Optogenetics merges genetic targeting with light-sensitive proteins. Researchers can activate or silence specific nerve cell groups using this approach. This control allows scientists to examine how particular circuits contribute to movement, learning, emotions, and memory. According to the Nobel Assembly, this technique transformed research on living brains. It also enabled laboratories to link activity in targeted cells with observable behavioral changes. Importantly, scientists can now study specific cells without stimulating broad tissue regions simultaneously.
Today, optogenetics is used to investigate disorders such as Parkinson’s disease, epilepsy, depression, addiction, and more. Researchers are also testing related methods for severe vision loss. Some experimental treatments aim to restore light sensitivity to retinal cells. These medical applications are still under development and are not yet standard care. The primary current use of the technique remains in research, where it helps scientists analyze complex biological systems with high accuracy. Its application has expanded beyond neuroscience into other fields of cell biology.
Three scientists share the Nobel prize in medicine
Deisseroth is based at Stanford University and is affiliated with the Howard Hughes Medical Institute in the United States. Hegemann works at Humboldt University of Berlin. Nagel is at the University of Würzburg in Germany. The trio will share 12 million Swedish kronor. Their work marks distinct but interconnected steps in developing modern optogenetics. These steps include discovering light-sensitive proteins, characterizing them, and using them to control nerve cells.
The award honors a scientific journey that started with a simple organism and revolutionized brain research. Channelrhodopsin acted as the molecular switch enabling precise light control. Deisseroth’s work helped bring that switch into nerve cells and living brains. Today, optogenetics is widely used across neuroscience and other biological sciences. The laureates will receive their Nobel medals and diplomas in Stockholm on December 10. This ceremony coincides with the anniversary of Alfred Nobel’s death, continuing a long-standing tradition.